THIS MESSAGE (MATERIAL) IS CREATED AND (OR) DISTRIBUTED BY A FOREIGN MASS MEDIA PERFORMING THE FUNCTIONS OF A FOREIGN AGENT AND (OR) A RUSSIAN LEGAL ENTITY PERFORMING THE FUNCTIONS OF A FOREIGN AGENT.
The American biopharmaceutical company AbbVie will stop supplying Botox and fillers to Russia, the most popular products in Russian aesthetic medicine.
As notes “businessman”, if Botox can be replaced at the expense of local manufacturers, then there are practically no alternatives to fillers.
AbbVie has imposed restrictions on work in Russia following Bayer, Pfizer, MSD and other global pharmaceutical manufacturers due to the situation in Ukraine. The company will not start new clinical trials and will suspend enrollment in ongoing trials in Russia and Ukraine. Refusal to supply products of aesthetic medicine was the most cardinal step.
At the same time, as noted, the supply of Botox (botulinum toxin type A) will not be completely suspended: Botulinum therapy is also used in urology and neurology, and AbbVie said it will continue to provide Russian patients with drugs.
On February 24, Russian President Vladimir Putin made an emergency appeal to the Russians and announced a special military operation in the Donbass. In his speech, he stated that “circumstances require decisive action from Russia” and stressed that “Russia will not allow Ukraine to have nuclear weapons.” In response to Russia’s actions, Western countries (USA, Canada, EU, UK, Japan) announced new, tougher sanctions against the Russian Federation, including financial and economic ones.
You can follow the chronicle of events in connection with the situation in Ukraine here.
Source: Rosbalt
Tristin is an accomplished author and journalist, known for his in-depth and engaging writing on sports. He currently works as a writer at 247 News Agency, where he has established himself as a respected voice in the sports industry.
